Tscan Therapeutics Inc

This management proposal seeks stockholder approval to amend the Company’s certificate of incorporation to double the number of authorized voting common shares from 300 million to 600 million (increasing total authorized capital to 620 million across classes). Management frames the change as necessary to preserve flexibility to issue shares for equity financings, satisfy equity compensation plan needs, support strategic transactions (including mergers and acquisitions), and provide working capital without needing immediate further stockholder approvals. The company states that, as of the record date, a meaningful portion of authorized shares were already reserved or issuable (including outstanding shares, issuable under equity plans, and shares issuable upon exercise of pre-funded warrants), leaving a constrained headroom for anticipated capital needs. The board argues that failing to increase authorized shares could hinder the company’s ability to access public and private capital markets and could materially impede operations or growth, potentially affecting going concern considerations. Adoption would enable rapid execution of financing and strategic transactions but would also create dilution risk for existing stockholders, dilute voting power, and could be used defensively to deter takeovers; the filing explicitly notes both the dilutive effect and the board’s discretion in using new shares. The board recommends a FOR vote, citing the need for capital flexibility and the identical rights of any additional voting common stock to existing voting shares; it also reserves the right to abandon the filing even if approved, providing the board discretion. Analysts should weigh the company’s cash runway and near-term financing needs, recent financing activity (including substantial issuances of pre-funded warrants), the existing large number of shares reserved under compensation plans, and potential dilution against the strategic necessity of preserving issuance capacity when evaluating the merits of this proposal.

This management proposal asks shareholders to authorize the board’s proxies to adjourn the Annual Meeting, if necessary, to solicit additional proxies so Proposal No. 3 (the authorized shares increase) can be approved. Practically, the proposal gives the board procedural flexibility to pause the meeting and continue outreach to shareholders—potentially including stockholders who previously voted—to secure the votes required to pass the charter amendment. The board frames this as a contingency measure to ensure that an important capital-authorizing item can be reconsidered without holding a separate special meeting, and notes that the Company does not intend to adjourn if sufficient votes are already present. While described as a routine procedural request, approval would permit the board to delay final action on Proposal No. 3 even if proxies currently favor defeat, enabling renewed solicitation and potentially altering the outcome. For investors, this raises governance considerations: while adjournment can be an efficient mechanism to complete important business, it can also be used to exert pressure on undecided holders or to change the timing and dynamics of a contentious vote. The board states customary limits (no separate notice required for adjournments under 30 days and no new record date), but shareholders should weigh the board’s rationale for additional solicitation against the potential for tactical use of adjournments in contested situations. Given the linkage to Proposal No. 3, analysts should evaluate the company’s near-term capital needs and the likelihood the board can materially change vote outcomes during an adjournment when assessing the strategic need for this approval.